Eda Nur Duran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eda Nur Duran has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Hafize Uzun
Department of Biochemistry, Faculty of Medicine, Istanbul Atlas University, Istanbul 34408, Turkey
4 shared publications - Omur Tabak
Department of Internal Medicine, Kanuni Sultan Suleyman Training and Research Hospital, Health Sciences University, 34303 Istanbul, Türkiye
4 shared publications - Iskender Ekinci
Department of Internal Medicine, Bezmialem Vakif University, Istanbul, Türkiye
3 shared publications - Berrak Sahtiyanci
Department of Internal Medicine, Istanbul Physical Therapy and Rehabilitation Training and Research Hospital, 34182 Istanbul, Türkiye
2 shared publications - Esra Demir
Department of Internal Medicine, Istanbul Medipol University, 34810 Istanbul, Türkiye
2 shared publications - Gulden Anataca
Kanuni Sultan Suleyman Training and Research Hospital, University of Health Sciences, Istanbul, Türkiye
2 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1602
Decreased Serum Salusin-β Levels Are Independently Associated with Gestational Diabetes Mellitus
Background: Gestational diabetes mellitus (GDM) is characterized by pregnancy-induced insulin resistance and β-cell dysfunction and is increasingly recognized as a state of cardiometabolic and endothelial dysregulation. Salusin-β, a bioactive peptide implicated in vascular inflammation and metabolic disorders, may play a role in GDM pathophysiology. However, data regarding its clinical relevance in GDM remain limited. Objective: This study aimed to compare serum salusin-β levels between women with GDM and healthy pregnant controls and to evaluate its diagnostic performance. Methods: This prospective study included 144 pregnant women between 24 and 28 weeks of gestation (70 with GDM and 74 healthy controls). GDM was diagnosed using a 75-g oral glucose tolerance test according to American Diabetes Association criteria. Serum salusin-β levels were measured using ELISA. Between-group comparisons were performed using appropriate parametric or non-parametric tests. Multivariable logistic regression analysis was performed to evaluate the independent association between salusin-β and GDM. Sensitivity analyses using an expanded adjustment model were also conducted. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Salusin-β levels were significantly lower in women with GDM compared to controls (68.53 [53.05–84.27] vs. 128.03 [76.74–261.35] pg/mL; p < 0.001). In the expanded multivariable logistic regression analysis, lower serum salusin-β levels remained independently associated with GDM (OR = 0.990, 95% CI: 0.985–0.996, p = 0.001). ROC analysis demonstrated acceptable discriminatory performance (AUC = 0.754, 95% CI: 0.672–0.833). The optimal cut-off value of 87.1 pg/mL yielded 80.0% sensitivity and 66.2% specificity. Conclusions: Serum salusin-β levels are significantly reduced in women with GDM and independently associated with disease presence. Although not sufficient as a standalone diagnostic marker, salusin-β demonstrates moderate discriminatory ability and may serve as a complementary biomarker reflecting vascular and metabolic dysregulation in GDM.
- 17 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (7) , 1602
Open AccessDecreased Serum Salusin-β Levels Are Independently Associated with Gestational Diabetes Mellitus
Background: Gestational diabetes mellitus (GDM) is characterized by pregnancy-induced insulin resistance and β-cell dysfunction and is increasingly recognized as a state of cardiometabolic and endothelial dysregulation. Salusin-β, a bioactive peptide implicated in vascular inflammation and metabolic disorders, may play a role in GDM pathophysiology. However, data regarding its clinical relevance in GDM remain limited. Objective: This study aimed to compare serum salusin-β levels between women with GDM and healthy pregnant controls and to evaluate its diagnostic performance. Methods: This prospective study included 144 pregnant women between 24 and 28 weeks of gestation (70 with GDM and 74 healthy controls). GDM was diagnosed using a 75-g oral glucose tolerance test according to American Diabetes Association criteria. Serum salusin-β levels were measured using ELISA. Between-group comparisons were performed using appropriate parametric or non-parametric tests. Multivariable logistic regression analysis was performed to evaluate the independent association between salusin-β and GDM. Sensitivity analyses using an expanded adjustment model were also conducted. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Salusin-β levels were significantly lower in women with GDM compared to controls (68.53 [53.05–84.27] vs. 128.03 [76.74–261.35] pg/mL; p < 0.001). In the expanded multivariable logistic regression analysis, lower serum salusin-β levels remained independently associated with GDM (OR = 0.990, 95% CI: 0.985–0.996, p = 0.001). ROC analysis demonstrated acceptable discriminatory performance (AUC = 0.754, 95% CI: 0.672–0.833). The optimal cut-off value of 87.1 pg/mL yielded 80.0% sensitivity and 66.2% specificity. Conclusions: Serum salusin-β levels are significantly reduced in women with GDM and independently associated with disease presence. Although not sufficient as a standalone diagnostic marker, salusin-β demonstrates moderate discriminatory ability and may serve as a complementary biomarker reflecting vascular and metabolic dysregulation in GDM.
- Open Access
- 22 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4002
Reduced Circulating MOTS-c Levels in Hashimoto’s Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study
Background: Hashimoto’s thyroiditis (HT) is a common autoimmune disorder characterized by chronic inflammation and metabolic alterations. Mitochondria-derived peptides (MDPs), particularly mitochondrial open-reading frame of the 12S rRNA-c (MOTS-c), have emerged as key regulators of cellular metabolism, insulin sensitivity, oxidative stress, and inflammatory responses. This study aimed to investigate the association between circulating MOTS-c levels and HT and to explore its potential role in thyroid autoimmunity and metabolic regulation. Methods: In this cross-sectional study, patients diagnosed with HT (n: 90) were compared with age- and sex-matched healthy controls (n: 90). Results: A total of 180 participants were included, comprising 90 patients with HT and 90 age- and sex-matched healthy controls. Circulating MOTS-c levels were significantly lower in patients with HT compared to controls (p < 0.001). MOTS-c levels demonstrated significant inverse correlations with body mass index, fasting glucose, HbA1c, HOMA-IR, thyroid-stimulating hormone, C-reactive protein, and thyroid autoantibody levels (all p < 0.05). In subgroup analyses, these associations remained significant within the HT cohort, particularly for HOMA-IR and thyroid autoantibodies. Multivariable regression analysis identified HT (β = −30.04, p < 0.001) and HOMA-IR (β = −0.85, p < 0.001) as independent determinants of reduced circulating MOTS-c levels. Levothyroxine (LT4) use was not associated with significant differences in MOTS-c concentrations. Conclusions: Circulating MOTS-c levels are markedly reduced in patients with HT and are independently associated with insulin resistance and autoimmune burden. These findings suggest that impaired mitochondrial signaling may play a role in the pathophysiology of thyroid autoimmunity and highlight MOTS-c as a promising biomarker linking metabolic dysfunction and immune dysregulation.
- 22 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4002
Open AccessReduced Circulating MOTS-c Levels in Hashimoto’s Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study
Background: Hashimoto’s thyroiditis (HT) is a common autoimmune disorder characterized by chronic inflammation and metabolic alterations. Mitochondria-derived peptides (MDPs), particularly mitochondrial open-reading frame of the 12S rRNA-c (MOTS-c), have emerged as key regulators of cellular metabolism, insulin sensitivity, oxidative stress, and inflammatory responses. This study aimed to investigate the association between circulating MOTS-c levels and HT and to explore its potential role in thyroid autoimmunity and metabolic regulation. Methods: In this cross-sectional study, patients diagnosed with HT (n: 90) were compared with age- and sex-matched healthy controls (n: 90). Results: A total of 180 participants were included, comprising 90 patients with HT and 90 age- and sex-matched healthy controls. Circulating MOTS-c levels were significantly lower in patients with HT compared to controls (p < 0.001). MOTS-c levels demonstrated significant inverse correlations with body mass index, fasting glucose, HbA1c, HOMA-IR, thyroid-stimulating hormone, C-reactive protein, and thyroid autoantibody levels (all p < 0.05). In subgroup analyses, these associations remained significant within the HT cohort, particularly for HOMA-IR and thyroid autoantibodies. Multivariable regression analysis identified HT (β = −30.04, p < 0.001) and HOMA-IR (β = −0.85, p < 0.001) as independent determinants of reduced circulating MOTS-c levels. Levothyroxine (LT4) use was not associated with significant differences in MOTS-c concentrations. Conclusions: Circulating MOTS-c levels are markedly reduced in patients with HT and are independently associated with insulin resistance and autoimmune burden. These findings suggest that impaired mitochondrial signaling may play a role in the pathophysiology of thyroid autoimmunity and highlight MOTS-c as a promising biomarker linking metabolic dysfunction and immune dysregulation.
- Open Access
- 17 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2297
Assessment of Pancreatic Exocrine Insufficiency in Patients with Dyspepsia: Clinical Utility of the PEI-Test in Identifying and Monitoring Response to Enzyme Replacement Therapy
Background and Objectives: Functional dyspepsia (FD) often overlaps with Pancreatic Exocrine Insufficiency (PEI), leading to diagnostic delays. We aimed to evaluate the prevalence of PEI in patients presenting dyspeptic symptoms using the survey-based PEI test and to assess the clinical response to Pancreatic Enzyme Replacement Therapy (PERT). Methods: This study included 91 patients with PEI and 58 control subjects. PEI was evaluated using the PEI Patient-Reported Outcome (PRO) instrument and classified as mild, moderate, or severe according to the 18-item PEI test. Objective fat malabsorption was assessed by the acid steatocrit method using a gravimetric assay. Patients diagnosed with PEI received PERT, and treatment response was evaluated at follow-up with a repeat PEI test. Results: When the case and control groups were compared in terms of PEI scores, a statistically significant difference was found (p < 0.001). Fecal steatocrit value was found to be statistically significant with the PEI score (p = 0.017). No statistically significant difference was found between amylase, lipase, vitamin D, vitamin B12, and folic acid and the PEI score (p = 0.789, p = 0.299, p = 0.865, p = 0.153, and p = 0.855, respectively). A statistically significant difference was found between the pre-treatment PEI score and the post-treatment PEI score (p < 0.001). The mean pre-treatment PEI score was 1.52 ± 0.50, while the post-treatment PEI score was 0.42 ± 0.48. Approximately 72% reduction in PEI score was observed with treatment. Conclusions: The PEI test may represent a useful, non-invasive tool for identifying suspected pancreatic dysfunction in patients initially diagnosed with functional dyspepsia. Early integration of this tool into clinical practice can improve symptom control and prevent the misclassification of PEI as a purely functional disorder.
- 17 March 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (6) , 2297
Open AccessAssessment of Pancreatic Exocrine Insufficiency in Patients with Dyspepsia: Clinical Utility of the PEI-Test in Identifying and Monitoring Response to Enzyme Replacement Therapy
Background and Objectives: Functional dyspepsia (FD) often overlaps with Pancreatic Exocrine Insufficiency (PEI), leading to diagnostic delays. We aimed to evaluate the prevalence of PEI in patients presenting dyspeptic symptoms using the survey-based PEI test and to assess the clinical response to Pancreatic Enzyme Replacement Therapy (PERT). Methods: This study included 91 patients with PEI and 58 control subjects. PEI was evaluated using the PEI Patient-Reported Outcome (PRO) instrument and classified as mild, moderate, or severe according to the 18-item PEI test. Objective fat malabsorption was assessed by the acid steatocrit method using a gravimetric assay. Patients diagnosed with PEI received PERT, and treatment response was evaluated at follow-up with a repeat PEI test. Results: When the case and control groups were compared in terms of PEI scores, a statistically significant difference was found (p < 0.001). Fecal steatocrit value was found to be statistically significant with the PEI score (p = 0.017). No statistically significant difference was found between amylase, lipase, vitamin D, vitamin B12, and folic acid and the PEI score (p = 0.789, p = 0.299, p = 0.865, p = 0.153, and p = 0.855, respectively). A statistically significant difference was found between the pre-treatment PEI score and the post-treatment PEI score (p < 0.001). The mean pre-treatment PEI score was 1.52 ± 0.50, while the post-treatment PEI score was 0.42 ± 0.48. Approximately 72% reduction in PEI score was observed with treatment. Conclusions: The PEI test may represent a useful, non-invasive tool for identifying suspected pancreatic dysfunction in patients initially diagnosed with functional dyspepsia. Early integration of this tool into clinical practice can improve symptom control and prevent the misclassification of PEI as a purely functional disorder.
- Open Access
- 9 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 559
Diagnostic Utility of Serum Activating Transcription Factor 4 and Toll-like Receptor 4 as Early Biomarkers of Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease
Background/Objectives: This study aimed to evaluate the serum activating transcription factor 4 (ATF4) and toll-like receptor 4 (TLR4) levels in patients with metabolic dysfunction–associated steatotic liver disease (MASLD), and to explain the mechanism in the inflammatory and fibrogenic signaling pathways that are thought to play a role in the development of MASLD through these parameters. Methods: Eighty-eight patients with MASLD and 88 age-sex matched healthy controls were included in this study. Serum ATF4 and TLR4 concentrations were measured using an ELISA method. Results: Both TLR4 (p = 0.010) and ATF4 (p < 0.001) levels were higher in the MASLD group. In this group, TLR4 showed a negative correlation with age. ROC analysis indicated that an ATF4 value of 1.305 or above identified MASLD with 93.2% sensitivity and 85.2% specificity (AUC = 0.968, p < 0.001). For TLR4, a cut-off of 343.5 yielded a sensitivity of 54.5% and a specificity of 70.5% (AUC = 0.613, p = 0.01), indicating limited discriminative ability. Conclusions: Patients with MASLD had higher serum TLR4 and ATF4 levels, consistent with their involvement in inflammatory and fibrotic pathways. ATF4 showed strong diagnostic performance and may serve as a useful non-invasive marker for early MASLD. When evaluated together with TLR4, it may provide complementary information regarding inflammatory pathway activation.
- 9 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 559
Open AccessDiagnostic Utility of Serum Activating Transcription Factor 4 and Toll-like Receptor 4 as Early Biomarkers of Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease
Background/Objectives: This study aimed to evaluate the serum activating transcription factor 4 (ATF4) and toll-like receptor 4 (TLR4) levels in patients with metabolic dysfunction–associated steatotic liver disease (MASLD), and to explain the mechanism in the inflammatory and fibrogenic signaling pathways that are thought to play a role in the development of MASLD through these parameters. Methods: Eighty-eight patients with MASLD and 88 age-sex matched healthy controls were included in this study. Serum ATF4 and TLR4 concentrations were measured using an ELISA method. Results: Both TLR4 (p = 0.010) and ATF4 (p < 0.001) levels were higher in the MASLD group. In this group, TLR4 showed a negative correlation with age. ROC analysis indicated that an ATF4 value of 1.305 or above identified MASLD with 93.2% sensitivity and 85.2% specificity (AUC = 0.968, p < 0.001). For TLR4, a cut-off of 343.5 yielded a sensitivity of 54.5% and a specificity of 70.5% (AUC = 0.613, p = 0.01), indicating limited discriminative ability. Conclusions: Patients with MASLD had higher serum TLR4 and ATF4 levels, consistent with their involvement in inflammatory and fibrotic pathways. ATF4 showed strong diagnostic performance and may serve as a useful non-invasive marker for early MASLD. When evaluated together with TLR4, it may provide complementary information regarding inflammatory pathway activation.
- Open Access
- 28 December 2025
- Published by MDPI AG in Diagnostics
- Vol. 16 (1) , 106
The Importance of Serum Perilipin-2 Level as an Early Indicator of Inflammation in Non-Alcoholic Fatty Liver Disease
Background/Objectives: Non-alcoholic fatty liver disease (NAFLD), also referred to as metabolic dysfunction-associated fatty liver disease (MAFLD), is the most common chronic liver disease, closely associated with obesity and Metabolic Syndrome (MetS). Perilipin-2 (PLIN2), the most abundant lipid droplet protein in the liver, is linked to lipid accumulation and inflammation, the hallmarks of NAFLD. The role of PLIN2 in NAFLD etiopathogenesis remains partially understood. This study aims to elucidate the relationship between serum PLIN2 levels and other disease-related parameters in NAFLD, investigate the role of PLIN2 in disease pathogenesis, and evaluate its utility as a biomarker in NAFLD diagnosis. Methods: The study included 46 patients diagnosed with NAFLD who presented internal medicine outpatient clinics and 44 healthy controls. Results: Serum PLIN2 level was found to be statistically significantly higher in the NAFLD patient group compared to the control group. In the NAFLD group, a statistically significant positive correlation was detected between PLIN2 and Body Mass Index (BMI), hip circumference, C-reactive protein (CRP), and platelet count. In ROC analysis, taking the cut-off value for serum PLIN2 level as 5.52 ng/mL predicted the diagnosis of NAFLD with 50% sensitivity and 97.7% specificity. Conclusions: PLIN2 determination demonstrated high specificity at the proposed cut-off value and may represent a promising complementary biomarker for NAFLD, particularly when interpreted alongside other clinical and laboratory parameters. Circulating PLIN2 appears to be influenced by metabolic and inflammatory parameters.
- 28 December 2025
- Published by MDPI AG in Diagnostics
- Vol. 16 (1) , 106
Open AccessThe Importance of Serum Perilipin-2 Level as an Early Indicator of Inflammation in Non-Alcoholic Fatty Liver Disease
Background/Objectives: Non-alcoholic fatty liver disease (NAFLD), also referred to as metabolic dysfunction-associated fatty liver disease (MAFLD), is the most common chronic liver disease, closely associated with obesity and Metabolic Syndrome (MetS). Perilipin-2 (PLIN2), the most abundant lipid droplet protein in the liver, is linked to lipid accumulation and inflammation, the hallmarks of NAFLD. The role of PLIN2 in NAFLD etiopathogenesis remains partially understood. This study aims to elucidate the relationship between serum PLIN2 levels and other disease-related parameters in NAFLD, investigate the role of PLIN2 in disease pathogenesis, and evaluate its utility as a biomarker in NAFLD diagnosis. Methods: The study included 46 patients diagnosed with NAFLD who presented internal medicine outpatient clinics and 44 healthy controls. Results: Serum PLIN2 level was found to be statistically significantly higher in the NAFLD patient group compared to the control group. In the NAFLD group, a statistically significant positive correlation was detected between PLIN2 and Body Mass Index (BMI), hip circumference, C-reactive protein (CRP), and platelet count. In ROC analysis, taking the cut-off value for serum PLIN2 level as 5.52 ng/mL predicted the diagnosis of NAFLD with 50% sensitivity and 97.7% specificity. Conclusions: PLIN2 determination demonstrated high specificity at the proposed cut-off value and may represent a promising complementary biomarker for NAFLD, particularly when interpreted alongside other clinical and laboratory parameters. Circulating PLIN2 appears to be influenced by metabolic and inflammatory parameters.
- Open Access
- 30 September 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Cognitive flexibility, memory, and attention in colorectal cancer: findings from a comprehensive neuropsychological assessment
Cognitive impairment is a recognized challenge for cancer survivors, often linked to chemotherapy’s neurotoxic effects. In colorectal cancer (CRC), this impact remains less understood despite emerging evidence. This study aims to evaluate cognitive flexibility, memory, and attention in colorectal cancer patients compared to healthy controls. This prospective study assessed cognitive function in 58 colorectal cancer patients and 32 healthy, age- and education-matched controls. Cognitive testing was conducted within four weeks of chemotherapy completion. Exclusion criteria included pre-existing cognitive issues, brain metastases, and medications affecting cognition. Tests included Sensory Perception, Total Learning Score, Long-Term Memory Score, Stroop Test, and Trail Making Test. The median age of the cancer group was 56.5 years (range: 29–70), while the median age for the control group was 52 years (range: 28–66). Cancer patients demonstrated significantly poorer performance across several cognitive domains. Total Learning Scores were notably lower in the cancer group (mean rank 40.23 vs. 55.05, p = 0.01), indicating reduced learning capacity. Trail Making Test A and B times were significantly longer for cancer patients (p = 0.004), reflecting deficits in visual attention and cognitive flexibility. Stroop Test performance also showed significant delays across all time points (p = 0.002 to p = 0.02), suggesting impaired processing speed and executive control. Subgroup analysis of stage IV patients revealed even greater deficits, with significantly lower Total Learning Scores (p = 0.001) and slower Trail Making Test completion times (p < 0.001). No significant differences emerged in sensory perception or long-term memory. The research revealed significant cognitive difficulties in colorectal cancer patients after undergoing chemotherapy, especially in areas such as learning, attention, and executive function, with the most severe impairments observed in those with stage IV cancer.
- 30 September 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Open AccessCognitive flexibility, memory, and attention in colorectal cancer: findings from a comprehensive neuropsychological assessment
Cognitive impairment is a recognized challenge for cancer survivors, often linked to chemotherapy’s neurotoxic effects. In colorectal cancer (CRC), this impact remains less understood despite emerging evidence. This study aims to evaluate cognitive flexibility, memory, and attention in colorectal cancer patients compared to healthy controls. This prospective study assessed cognitive function in 58 colorectal cancer patients and 32 healthy, age- and education-matched controls. Cognitive testing was conducted within four weeks of chemotherapy completion. Exclusion criteria included pre-existing cognitive issues, brain metastases, and medications affecting cognition. Tests included Sensory Perception, Total Learning Score, Long-Term Memory Score, Stroop Test, and Trail Making Test. The median age of the cancer group was 56.5 years (range: 29–70), while the median age for the control group was 52 years (range: 28–66). Cancer patients demonstrated significantly poorer performance across several cognitive domains. Total Learning Scores were notably lower in the cancer group (mean rank 40.23 vs. 55.05, p = 0.01), indicating reduced learning capacity. Trail Making Test A and B times were significantly longer for cancer patients (p = 0.004), reflecting deficits in visual attention and cognitive flexibility. Stroop Test performance also showed significant delays across all time points (p = 0.002 to p = 0.02), suggesting impaired processing speed and executive control. Subgroup analysis of stage IV patients revealed even greater deficits, with significantly lower Total Learning Scores (p = 0.001) and slower Trail Making Test completion times (p < 0.001). No significant differences emerged in sensory perception or long-term memory. The research revealed significant cognitive difficulties in colorectal cancer patients after undergoing chemotherapy, especially in areas such as learning, attention, and executive function, with the most severe impairments observed in those with stage IV cancer.